The global mental health clinical trials market size is calculated at USD 3.44 billion in 2025 and is forecasted to reach around USD 7.00 billion by 2034, accelerating at a CAGR of 8.24% from 2025 to 2034. The North America market size surpassed USD 1.62 billion in 2024 and is expanding at a CAGR of 8.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Mental Health Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Mental Health Clinical Trials Market, by Phase
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase II
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast
9.1. Mental Health Clinical Trials Market, by Study Design
9.1.1. Interventional
9.1.1.1. Market Revenue and Forecast
9.1.2. Observational
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Mental Health Clinical Trials Market, by Sponsor
10.1.1. Pharmaceutical & Biopharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Government Agencies
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Mental Health Clinical Trials Market, by Disorder
11.1.1. Anxiety Disorders
11.1.1.1. Market Revenue and Forecast
11.1.2. Depression
11.1.2.1. Market Revenue and Forecast
11.1.3. Bipolar Affective Disorder
11.1.3.1. Market Revenue and Forecast
11.1.4. Bipolar Affective Disorder
11.1.4.1. Market Revenue and Forecast
11.1.5. Schizophrenia
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Phase
12.1.2. Market Revenue and Forecast, by Study Design
12.1.3. Market Revenue and Forecast, by Sponsor
12.1.4. Market Revenue and Forecast, by Disorder
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Phase
12.1.5.2. Market Revenue and Forecast, by Study Design
12.1.5.3. Market Revenue and Forecast, by Sponsor
12.1.5.4. Market Revenue and Forecast, by Disorder
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Phase
12.1.6.2. Market Revenue and Forecast, by Study Design
12.1.6.3. Market Revenue and Forecast, by Sponsor
12.1.6.4. Market Revenue and Forecast, by Disorder
12.2. Europe
12.2.1. Market Revenue and Forecast, by Phase
12.2.2. Market Revenue and Forecast, by Study Design
12.2.3. Market Revenue and Forecast, by Sponsor
12.2.4. Market Revenue and Forecast, by Disorder
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Phase
12.2.5.2. Market Revenue and Forecast, by Study Design
12.2.5.3. Market Revenue and Forecast, by Sponsor
12.2.5.4. Market Revenue and Forecast, by Disorder
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Phase
12.2.6.2. Market Revenue and Forecast, by Study Design
12.2.6.3. Market Revenue and Forecast, by Sponsor
12.2.6.4. Market Revenue and Forecast, by Disorder
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Phase
12.2.7.2. Market Revenue and Forecast, by Study Design
12.2.7.3. Market Revenue and Forecast, by Sponsor
12.2.7.4. Market Revenue and Forecast, by Disorder
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Phase
12.2.8.2. Market Revenue and Forecast, by Study Design
12.2.8.3. Market Revenue and Forecast, by Sponsor
12.2.8.4. Market Revenue and Forecast, by Disorder
12.3. APAC
12.3.1. Market Revenue and Forecast, by Phase
12.3.2. Market Revenue and Forecast, by Study Design
12.3.3. Market Revenue and Forecast, by Sponsor
12.3.4. Market Revenue and Forecast, by Disorder
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Phase
12.3.5.2. Market Revenue and Forecast, by Study Design
12.3.5.3. Market Revenue and Forecast, by Sponsor
12.3.5.4. Market Revenue and Forecast, by Disorder
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Phase
12.3.6.2. Market Revenue and Forecast, by Study Design
12.3.6.3. Market Revenue and Forecast, by Sponsor
12.3.6.4. Market Revenue and Forecast, by Disorder
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Phase
12.3.7.2. Market Revenue and Forecast, by Study Design
12.3.7.3. Market Revenue and Forecast, by Sponsor
12.3.7.4. Market Revenue and Forecast, by Disorder
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Phase
12.3.8.2. Market Revenue and Forecast, by Study Design
12.3.8.3. Market Revenue and Forecast, by Sponsor
12.3.8.4. Market Revenue and Forecast, by Disorder
12.4. MEA
12.4.1. Market Revenue and Forecast, by Phase
12.4.2. Market Revenue and Forecast, by Study Design
12.4.3. Market Revenue and Forecast, by Sponsor
12.4.4. Market Revenue and Forecast, by Disorder
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Phase
12.4.5.2. Market Revenue and Forecast, by Study Design
12.4.5.3. Market Revenue and Forecast, by Sponsor
12.4.5.4. Market Revenue and Forecast, by Disorder
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Phase
12.4.6.2. Market Revenue and Forecast, by Study Design
12.4.6.3. Market Revenue and Forecast, by Sponsor
12.4.6.4. Market Revenue and Forecast, by Disorder
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Phase
12.4.7.2. Market Revenue and Forecast, by Study Design
12.4.7.3. Market Revenue and Forecast, by Sponsor
12.4.7.4. Market Revenue and Forecast, by Disorder
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Phase
12.4.8.2. Market Revenue and Forecast, by Study Design
12.4.8.3. Market Revenue and Forecast, by Sponsor
12.4.8.4. Market Revenue and Forecast, by Disorder
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Phase
12.5.2. Market Revenue and Forecast, by Study Design
12.5.3. Market Revenue and Forecast, by Sponsor
12.5.4. Market Revenue and Forecast, by Disorder
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Phase
12.5.5.2. Market Revenue and Forecast, by Study Design
12.5.5.3. Market Revenue and Forecast, by Sponsor
12.5.5.4. Market Revenue and Forecast, by Disorder
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Phase
12.5.6.2. Market Revenue and Forecast, by Study Design
12.5.6.3. Market Revenue and Forecast, by Sponsor
12.5.6.4. Market Revenue and Forecast, by Disorder
13.1. ICON Plc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Caidya
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Syneous Health
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novo Nordisk
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pharmaceutical Product Development, LLC
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Parexel International Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Corcept
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample